Publications

1. Ha Y, Rajani K, Riviere-Cazaux C, Rahman M, Olson IE, Gharibi Loron A, Schroeder MA, Rodriguez M, Warrington AE, Burns TC. An Injury-like Signature of the Extracellular Glioma Metabolome. Cancers (Basel). 2024 Jul 30; 16(15).
   View PubMed
2. Riviere-Cazaux C, Rajani K, Rahman M, Oh J, Brown DA, White JF, Himes BT, Jusue-Torres I, Rodriguez M, Warrington AE, Kizilbash SH, Elmquist WF, Burns TC. Methodological and analytical considerations for intra-operative microdialysis. Fluids Barriers CNS. 2023 Dec 19; 20 (1):94
   View PubMed
3. Riviere-Cazaux C, Carlstrom LP, Neth BJ, Olson IE, Rajani K, Rahman M, Ikram S, Mansour MA, Mukherjee B, Warrington AE, Short SC, von Zglinicki T, Brown DA, Burma S, Tchkonia T, Schafer MJ, Baker DJ, Kizilbash SH, Kirkland JL, Burns TC. An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence. NPJ Precis Oncol. 2023 Nov 29; 7 (1):126
   View PubMed
4. Riviere-Cazaux C, Carlstrom LP, Rajani K, Munoz-Casabella A, Rahman M, Gharibi-Loron A, Brown DA, Miller KJ, White JJ, Himes BT, Jusue-Torres I, Ikram S, Ransom SC, Hirte R, Oh JH, Elmquist WF, Sarkaria JN, Vaubel RA, Rodriguez M, Warrington AE, Kizilbash SH, Burns TC. Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas. Commun Biol. 2023 Jun 20; 6 (1):653 Epub 2023 June 20
   View PubMed
5. Riviere-Cazaux C, Lacey JM, Carlstrom LP, Laxen WJ, Munoz-Casabella A, Hoplin MD, Ikram S, Zubair AB, Andersen KM, Warrington AE, Decker PA, Kaufmann TJ, Campian JL, Eckel-Passow JE, Kizilbash SH, Tortorelli S, Burns TC. Cerebrospinal fluid 2-hydroxyglutarate (2-HG) as a monitoring biomarker for IDH-mutant gliomas. medRxiv. 2023 Mar 2.
   
6. Mansour MA, Rahman M, Ayad AA, Warrington AE, Burns TC. P21 Overexpression Promotes Cell Death and Induces Senescence in Human Glioblastoma. Cancers (Basel). 2023 Feb 17; 15 (4)
   View PubMed
7. Riviere-Cazaux C, Lacey JM, Carlstrom LP, Laxen WJ, Munoz-Casabella A, Hoplin MD, Ikram S, Zubair AB, Andersen KM, Warrington AE, Decker PA, Kaufmann TJ, Campian JL, Eckel-Passow JE, Kizilbash SH, Tortorelli S, Burns TC. Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas. Neurooncol Adv. 2023 Jan-Dec; 5 (1):vdad061 Epub 2023 May 11
   View PubMed
8. Rahman M, Olson I, Mansour M, Carlstrom LP, Sutiwisesak R, Saber R, Rajani K, Warrington AE, Howard A, Schroeder M, Chen S, Decker PA, Sananikone EF, Zhu Y, Tchkonia T, Parney IF, Burma S, Brown D, Rodriguez M, Sarkaria JN, Kirkland JL, Burns TC. Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. Mol Cancer Res. 2022 Jun 3; 20 (6):938-948
   View PubMed
9. Greenberg BM, Bowen JD, Alvarez E, Rodriguez M, Caggiano AO, Warrington AE, Zhao P, Eisen A. A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. Mult Scler J Exp Transl Clin. 2022 Apr-Jun; 8 (2):20552173221091475 Epub 2022 Apr 26
   View PubMed
10. Sutiwisesak R, Burns TC, Rodriguez M, Warrington AE. Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials. Expert Opin Investig Drugs. 2021 Aug; 30 (8):857-876 Epub 2021 June 24
    View PubMed
11. Fereidan-Esfahani M, Yue WY, Wilbanks B, Johnson AJ, Warrington AE, Howe CL, Rodriguez M, Maher LJ 3rd. Remyelination-Promoting DNA Aptamer Conjugate Myaptavin-3064 Binds to Adult Oligodendrocytes In Vitro. Pharmaceuticals (Basel). 2020 Nov 19; 13 (11)
    View PubMed
12. Hayden L, Semenoff T, Schultz V, Merz SF, Chapple KJ, Rodriguez M, Warrington AE, Shi X, McKimmie CS, Edgar JM, Thummler K, Linington C, Pingen M. Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis. Acta Neuropathol Commun. 2020 Aug 13; 8 (1):135
    View PubMed
13. Stafford P, Johnston SA, Kantarci OH, Zare-Shahabadi A, Warrington A, Rodriguez M. Antibody characterization using immunosignatures. PLoS One. 2020; 15 (3):e0229080 Epub 2020 Mar 20
    View PubMed
14. Wilbanks B, Smestad J, Heider RM, Warrington AE, Rodriguez M, Maher LJ 3rd. Optimization of a 40-mer Antimyelin DNA Aptamer Identifies a 20-mer with Enhanced Properties for Potential Multiple Sclerosis Therapy. Nucleic Acid Ther. 2019 Jun; 29 (3):126-135 Epub 2019 Mar 11
    View PubMed
15. Fereidan-Esfahani M, Nayfeh T, Warrington A, Howe CL, Rodriguez M. IgM Natural Autoantibodies in Physiology and the Treatment of Disease. Methods Mol Biol. 2019; 1904:53-81
    View PubMed
16. Vala M, Jordan LR, Warrington AE, Maher LJ 3rd, Rodriguez M, Wittenberg NJ, Oh SH. Surface Plasmon Resonance Sensing on Naturally Derived Membranes: A Remyelination-Promoting Human Antibody Binds Myelin with Extraordinary Affinity. Anal Chem. 2018 Nov 6; 90 (21):12567-12573 Epub 2018 Oct 15
    View PubMed
17. Heider RM, Smestad JA, Lemus HN, Wilbanks B, Warrington AE, Peters JP, Rodriguez M, Maher LJ 3rd. An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis. Mol Ther Methods Clin Dev. 2018 Jun 15; 9:270-277 Epub 2018 Mar 21
    View PubMed
18. Perwein MK, Smestad JA, Warrington AE, Heider RM, Kaczor MW, Maher LJ 3rd, Wootla B, Kunbaz A, Rodriguez M. A comparison of human natural monoclonal antibodies and aptamer conjugates for promotion of CNS remyelination: where are we now and what comes next? Expert Opin Biol Ther. 2018 May; 18 (5):545-560 Epub 2018 Feb 25
    View PubMed
19. Lemus HN, Warrington AE, Rodriguez M. Multiple Sclerosis: Mechanisms of Disease and Strategies for Myelin and Axonal Repair. Neurol Clin. 2018 Feb; 36 (1):1-11
    View PubMed
20. Ryu YS, Jordan LR, Wittenberg NJ, Kim SM, Yoo D, Jeong C, Warrington AE, Rodriguez M, Oh SH, Lee SD. Curvature elasticity-driven leaflet asymmetry and interleaflet raft coupling in supported membranes Advanced Materials Interfaces. 2018; 5 (23):1801290
    
21. Rajani KR, Carlstrom LP, Parney IF, Johnson AJ, Warrington AE, Burns TC. Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. Front Oncol. 2018; 8:656 Epub 2019 Feb 22
    View PubMed
22. Kunbaz A, Warrington AE, Perwein MK, Fereidan-Esfahani M, Rodriguez M. A natural human monoclonal antibody protects from axonal injury in different CNS degenerative disease models Future Neurology. 2018; 13 (1):23-9
    
23. Lemus HN, Warrington AE, Denic A, Wootla B, Rodriguez M. Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis. Hum Antibodies. 2017; 25 (3-4):121-129
    View PubMed
24. Wootla B, Denic A, Watzlawik JO, Warrington AE, Zoecklein LJ, Papke-Norton LM, David C, Rodriguez M. Human class I major histocompatibility complex alleles determine central nervous system injury versus repair. J Neuroinflammation. 2016 Nov 17; 13 (1):293
    View PubMed
25. Wootla B, Denic A, Watzlawik JO, Warrington AE, Rodriguez M. Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease. Mol Neurobiol. 2016 Oct; 53 (8):5217-28 Epub 2015 Sept 26
    View PubMed
26. Dasari H, Wootla B, Warrington AE, Rodriguez M. Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis. Int J Phys Med Rehabil. 2016 Aug; 4 (4) Epub 2016 June 23
    View PubMed
27. Watzlawik JO, Kahoud RJ, Wootla B, Painter MM, Warrington AE, Carey WA, Rodriguez M. Antibody Binding Specificity for Kappa (Vkappa) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study. J Vis Exp. 2016 Jun 29; (112) Epub 2016 June 29
    View PubMed
28. Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA, Henley JR, Oh SH, Warrington AE, Rodriguez M. Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther. 2016 Jun; 16 (6):827-839 Epub 2016 Mar 10
    View PubMed
29. Wootla B, Denic A, Warrington AE, Rodriguez M. A monoclonal natural human IgM protects axons in the absence of remyelination. J Neuroinflammation. 2016 Apr 28; 13 (1):94
    View PubMed
30. Painter MM, Morrison JH, Zoecklein LJ, Rinkoski TA, Watzlawik JO, Papke LM, Warrington AE, Bieber AJ, Matchett WE, Turkowski KL, Poeschla EM, Rodriguez M. Antiviral Protection via RdRP-Mediated Stable Activation of Innate Immunity. PLoS Pathog. 2015 Dec; 11 (12):e1005311 Epub 2015 Dec 03
    View PubMed
31. Wootla B, Watzlawik JO, Warrington AE, Wittenberg NJ, Denic A, Xu X, Jordan LR, Papke LM, Zoecklein LJ, Pierce ML, Oh SH, Kantarci OH, Rodriguez M. Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases. JAMA Neurol. 2015 Nov; 72: (11)1346-53.
    View PubMed
32. Watzlawik JO, Kahoud RJ, Ng S, Painter MM, Papke LM, Zoecklein L, Wootla B, Warrington AE, Carey WA, Rodriguez M. Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders. J Neurochem. 2015 Sep; 134 (5):865-78 Epub 2015 Apr 27
    View PubMed
33. Xu X, Denic A, Jordan LR, Wittenberg NJ, Warrington AE, Wootla B, Papke LM, Zoecklein LJ, Yoo D, Shaver J, Oh SH, Pease LR, Rodriguez M. A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. Dis Model Mech. 2015 Aug 1; 8 (8):831-42 Epub 2015 May 28
    View PubMed
34. Wootla B, Denic A, Watzlawik JO, Warrington AE, Rodriguez M. A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis. J Neuroinflammation. 2015 Apr 29; 12:83
    View PubMed
35. Perschbacher K, Smestad JA, Peters JP, Standiford MM, Denic A, Wootla B, Warrington AE, Rodriguez M, Maher LJ 3rd. Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice. Nucleic Acid Ther. 2015 Feb; 25 (1):11-9 Epub 2014 Dec 23
    View PubMed
36. Xu X, Ng SM, Hassouna E, Warrington A, Oh SH, Rodriguez M. Human-derived natural antibodies: biomarkers and potential therapeutics. Future Neurol. 2015; 10 (1):25-39
    View PubMed
37. Wittenberg NJ, Johnson TW, Jordan LR, Xu X, Warrington AE, Rodriguez M, Oh SH. Formation of biomembrane microarrays with a squeegee-based assembly method. J Vis Exp. 2014 May 8; (87) Epub 2014 May 08
    View PubMed
38. Wittenberg NJ, Wootla B, Jordan LR, Denic A, Warrington AE, Oh SH, Rodriguez M. Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases. Expert rev. neurotherapeutics. 2014; 14(4):449-63.
    
39. Watzlawik JO, Wootla B, Painter MM, Warrington AE, Rodriguez M. Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire. Expert Rev Neurother. 2013 Sep; 13 (9):1017-29
    View PubMed
40. Jordan L, Xu X, Wittenberg NJ, Warrington AE, Denic A, Wootla B, Yoo D, Watzlawik J, Rodriguez M, Oh SH. Measuring binding interactions of neurite-extension promoting antibodies to supported lipid membranes using a multichannel microfluidic plasmonic nanohole array biosensor. 17th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2013. 2013; 1:215-7.
    
41. Xu X, Wittenberg NJ, Jordan LR, Kumar S, Watzlawik JO, Warrington AE, Oh SH, Rodriguez M. A patterned recombinant human IgM guides neurite outgrowth of CNS neurons. Sci Rep. 2013; 3:2267
    View PubMed
42. Watzlawik JO, Warrington AE, Rodriguez M. PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation. PLoS One. 2013; 8 (2):e55149 Epub 2013 Feb 01
    View PubMed
43. Xu X, Denic A, Warrington AE, Bieber AJ, Rodriguez M. Therapeutics to promote CNS repair: a natural human neuron-binding IgM regulates membrane-raft dynamics and improves motility in a mouse model of multiple sclerosis. J Clin Immunol. 2013 Jan; 33 Suppl 1:S50-6 Epub 2012 Sept 19
    View PubMed
44. Wittenberg NJ, Im H, Xu X, Wootla B, Watzlawik J, Warrington AE, Rodriguez M, Oh SH. High-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance. Anal Chem. 2012 Jul 17; 84(14):6031-9. Epub 2012 Jul 03.
    View PubMed
45. Wootla B, Denic A, Warrington AE, Rodriguez M. Need for a paradigm shift in therapeutic approaches to CNS injury. Expert Rev Neurother. 2012 Apr; 12 (4):409-20
    View PubMed
46. Warrington AE, Van Keulen V, Pease LR, Rodriguez M. Naturally occurring antibodies as therapeutics for neurologic disease: can human monoclonal IgMs replace the limited resource IVIG? Adv Exp Med Biol. 2012; 750:44-55.
    View PubMed
47. Nastasijevic B, Wright BR, Smestad J, Warrington AE, Rodriguez M, Maher LJ 3rd. Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis. PLoS One. 2012; 7 (6):e39595 Epub 2012 June 27
    View PubMed
48. Xu X, Warrington AE, Wright BR, Bieber AJ, Van Keulen V, Pease LR, Rodriguez M. A human IgM signals axon outgrowth: coupling lipid raft to microtubules. J Neurochem. 2011 Oct; 119 (1):100-12 Epub 2011 Sept 01
    View PubMed
49. Wittenberg NJ, Im H, Johnson TW, Xu X, Warrington AE, Rodriguez M, Oh SH. Facile assembly of micro- and nanoarrays for sensing with natural cell membranes. ACS Nano. 2011 Sep 27; 5(9):7555-64. Epub 2011 Aug 17.
    View PubMed
50. Denic A, Zoecklein L, Kerkvliet J, Papke L, Edukulla R, Warrington A, Bieber A, Pease LR, David CS, Rodriguez M. Transgenic expression of viral capsid proteins predisposes to axonal injury in a murine model of multiple sclerosis. Brain Pathol. 2011 Sep; 21 (5):501-15 Epub 2011 Feb 11
    View PubMed
51. Wootla B, Lacroix-Desmazes S, Warrington AE, Bieber AJ, Kaveri SV, Rodriguez M. Autoantibodies with enzymatic properties in human autoimmune diseases. J Autoimmun. 2011 Sep; 37 (2):144-50 Epub 2011 May 31
    View PubMed
52. Xu X, Warrington AE, Bieber AJ, Rodriguez M. Enhancing CNS repair in neurological disease: challenges arising from neurodegeneration and rewiring of the network. CNS Drugs. 2011 Jul; 25 (7):555-73
    View PubMed
53. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011 Feb; 18 (1):21-9
    View PubMed
54. Wittenberg NJ, Im H, Warrington AE, Rodriguez M, Oh SH. Plasmonic nanopore arrays for characterizing the binding of myelin growth promoting igm antibodies to supported lipid bilayers. 15th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2011, MicroTAS 2011. 2011; 2:1089-91.
    
55. Denic A, Macura SI, Warrington AE, Pirko I, Grossardt BR, Pease LR, Rodriguez M. A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination. PLoS One. 2011; 6 (10):e26001 Epub 2011 Oct 12
    View PubMed
56. Wootla B, Denic A, Keegan BM, Winters JL, Astapenko D, Warrington AE, Bieber AJ, Rodriguez M. Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis. Neurol Res Int. 2011; 2011:780712 Epub 2011 Sept 22
    View PubMed
57. Watzlawik J, Holicky E, Edberg DD, Marks DL, Warrington AE, Wright BR, Pagano RE, Rodriguez M. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia. 2010 Nov 15; 58 (15):1782-93
    View PubMed
58. Warrington AE, Rodriguez M. Method of identifying natural antibodies for remyelination. J Clin Immunol. 2010 May; 30 Suppl 1:S50-5
    View PubMed
59. Watzlawik J, Warrington AE, Rodriguez M. Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination. Expert Rev Neurother. 2010 Mar; 10 (3):441-57
    View PubMed
60. Wright BR, Warrington AE, Edberg DD, Rodriguez M. "Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies": Correction. Arch Neurol. 2010 Feb; 67(2):147.
    
61. Wright BR, Warrington AE, Edberg DD, Rodriguez M. Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies. Arch Neurol. 2009 Dec; 66 (12):1456-9
    View PubMed
62. Denic A, Bieber A, Warrington A, Mishra PK, Macura S, Rodriguez M. Brainstem 1H nuclear magnetic resonance (NMR) spectroscopy: marker of demyelination and repair in spinal cord. Ann Neurol. 2009 Oct; 66 (4):559-64
    View PubMed
63. Rodriguez M, Warrington AE, Pease LR. Invited article: human natural autoantibodies in the treatment of neurologic disease. Neurology. 2009 Apr 7; 72 (14):1269-76
    View PubMed
64. Lesuffleur A, Lim KS, Lindquist NC, Im H, Warrington AE, Rodriguez M, Oh SH. Plasmonic nanohole arrays for label-free kinetic biosensing in a lipid membrane environment. Proceedings of the 31st Annual International Conference of the IEEE Engineering in Medicine and Biology Society: Engineering the Future of Biomedicine, EMBC. 2009 2009:1481-4.
    
65. Maynard JA, Lindquist NC, Sutherland JN, Lesuffleur A, Warrington AE, Rodriguez M, Oh SH. Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnology Journal. 2009; 4(11):1542-58.
    
66. Warrington AE, Rodriguez M. Remyelination-promoting human IgMs: developing a therapeutic reagent for demyelinating disease. Curr Top Microbiol Immunol. 2008; 318:213-39
    View PubMed
67. Warrington AE, Bieber AJ, Ciric B, Pease LR, Van Keulen V, Rodriguez M. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res. 2007 Apr; 85 (5):967-76
    View PubMed
68. Rodriguez M, Zoecklein L, Gamez JD, Pavelko KD, Papke LM, Nakane S, Howe C, Radhakrishnan S, Hansen MJ, David CS, Warrington AE, Pease LR. STAT4- and STAT6-signaling molecules in a murine model of multiple sclerosis. FASEB J. 2006 Feb; 20(2):343-5. Epub 2005 Dec 13
    View PubMed
69. Pirko I, Ciric B, Gamez J, Bieber AJ, Warrington AE, Johnson AJ, Hanson DP, Pease LR, Macura SI, Rodriguez M. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J. 2004 Oct; 18 (13):1577-9 Epub 2004 Aug 19
    View PubMed
70. Warrington AE, Bieber AJ, Van Keulen V, Ciric B, Pease LR, Rodriguez M. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol. 2004 May; 63 (5):461-73
    View PubMed
71. Howe CL, Bieber AJ, Warrington AE, Pease LR, Rodriguez M. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis. 2004 Feb; 15 (1):120-31
    View PubMed
72. Ciric B, Howe CL, Paz Soldan M, Warrington AE, Bieber AJ, Van Keulen V, Rodriguez M, Pease LR. Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol. 2003 Oct; 13 (4):608-16
    View PubMed
73. Paz Soldan MM, Warrington AE, Bieber AJ, Ciric B, Van Keulen V, Pease LR, Rodriguez M. Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci. 2003 Jan; 22 (1):14-24
    View PubMed
74. Mitsunaga Y, Ciric B, Van Keulen V, Warrington AE, Paz Soldan M, Bieber AJ, Rodriguez M, Pease LR. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J. 2002 Aug; 16 (10):1325-7 Epub 2002 June 21
    View PubMed
75. Bieber AJ, Warrington A, Asakura K, Ciric B, Kaveri SV, Pease LR, Rodriguez M. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia. 2002 Mar 1; 37 (3):241-9
    View PubMed
76. Bieber AJ, Warrington A, Warrington A, Pease LR, Rodriguez M, Rodriguez M. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci. 2001 Nov; 24 (11 Suppl):S39-44
    View PubMed
77. Warrington AE, Bieber AJ, Ciric B, Van Keulen V, Pease LR, Mitsunaga Y, Paz Soldan MM, Rodriguez M, Rodriguez M. Immunoglobulin-mediated CNS repair. J Allergy Clin Immunol. 2001 Oct; 108 (4 Suppl):S121-5
    View PubMed
78. Bieber A, Asakura K, Warrington A, Kaveri SV, Rodriguez M. Antibody-mediated remyelination: relevance to multiple sclerosis. Mult Scler. 2000 Oct 6; (Suppl 2):S1-5, discussion S33.
    
79. Warrington AE, Asakura K, Bieber AJ, Ciric B, Van Keulen V, Kaveri SV, Kyle RA, Pease LR, Rodriguez M. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A. 2000 Jun 6; 97 (12):6820-5
    View PubMed
80. Gonye GE, Warrington AE, DeVito JA, Pfeiffer SE. Oligodendrocyte precursor quantitation and localization in perinatal brain using a retrospective bioassay. J Neurosci. 1994 Sep; 14(9):5365-72.
    View PubMed
81. Pfeiffer SE, Warrington AE, Bansal R. The oligodendrocyte and its many cellular processes. Trends Cell Biol. 1993 Jun; 3(6):191-7.
    View PubMed
82. Warrington AE, Barbarese E, Pfeiffer SE. Differential myelinogenic capacity of specific developmental stages of the oligodendrocyte lineage upon transplantation into hypomyelinating hosts. J Neurosci Res. 1993 Jan; 34(1):1-13.
    View PubMed
83. Warrington AE, Pfeiffer SE. Proliferation and differentiation of O4+ oligodendrocytes in postnatal rat cerebellum: analysis in unfixed tissue slices using anti-glycolipid antibodies. J Neurosci Res. 1992 Oct; 33(2):338-53.
    View PubMed
84. Warrington AE, Barbarese E, Pfeiffer SE. Stage specific, (O4+GalC-) isolated oligodendrocyte progenitors produce MBP+ myelin in vivo. Dev Neurosci. 1992; 14(2):93-7.
    View PubMed
85. Bansal R, Warrington AE, Gard AL, Ranscht B, Pfeiffer SE. Multiple and novel specificities of monoclonal antibodies O1, O4, and R-mAb used in the analysis of oligodendrocyte development. J Neurosci Res. 1989 Dec; 24(4):548-57.
    View PubMed
86. Gard AL, Warrington AE, Pfeiffer SE. A direct microculture ELISA system for studying brain development in culture: oligodendrocytes. J Neurosci Res. 1988; 19:46-53.